Evidence map›Paper›PMID 40397137›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Therapeutic evaluation of [

Anna Julie Kjøl Høyvik, Monika Kvassheim, Li-Wei Ma, Elisabeth Wiig, Tiril Hillestad, Mona-Elisabeth Revheim, Rugile Liukaityte, Øyvind Bruland, Asta Juzeniene

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Towards Dual-Tracer SPECT for Prostate Cancer Imaging Using [Pharmaceuticals (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anna Julie Kjøl HøyvikDepartment of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, 0379, Norway.
Monika KvassheimFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, 0318, Norway.
Li-Wei MaDepartment of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, 0379, Norway.
Elisabeth WiigDepartment of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, 0379, Norway.
Tiril HillestadDepartment of Core Facilities, Institute for Cancer Research and Molecular Imaging, Oslo University Hospital, Oslo, 0379, Norway.
Mona-Elisabeth RevheimFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, 0318, Norway.
Rugile LiukaityteDepartment of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, 0379, Norway.
Øyvind BrulandFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, 0318, Norway.
Asta JuzenieneDepartment of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, 0379, Norway. astaj@ous-hf.no.ORCID 0000-0001-9426-0062

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetastatic castration-resistant prostate cancer (mCRPC) frequently leads to bone and soft tissue metastases, leading to poor prognosis. The beta-emitting radioligand [

methodsBinding and internalisation of radioligands were evaluated in PC-3 PIP-luc cells. A mouse model was established by intracardiac injection of these cells. Treatments with 0.24‒1.0 MBq [

resultsBoth radioligands displayed comparable in vitro binding. In vivo studies revealed metastatic formation in clinically relevant organs. µPET/µCT demonstrated increased [

conclusion[

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingLead RadioisotopesLutetiumProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsAnimalsCell Line, TumorDisease Models, AnimalHumansMaleMiceNeoplasm MetastasisProstate-Specific AntigenTissue DistributionDipeptidesHeterocyclic Compounds, 1-RingLead-212Lead RadioisotopesLutetiumLutetium-177Prostate-Specific AntigenPSMA-617RadioisotopesRadiopharmaceuticals177Lu212PbDisseminated prostate cancer modelPSMATargeted alpha therapy

Identifiers

PMID40397137
PMCPMC12589369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.